Peregrine looks to redefine bavituximab as immunotherapy
This article was originally published in Scrip
Executive Summary
Peregrine Pharmaceuticals is riding the immunotherapy wave rippling through cancer drug development to resurrect its lead therapeutic candidate bavituximab following multiple clinical failures and a positive lung cancer study viewed with some skepticism following a data mix-up.